{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=SUBLOCADE&page=7", "query": { "intervention": "SUBLOCADE", "page": 7 }, "page_size": 10 }, "pagination": { "page": 7, "page_size": 10, "total_count": 621, "total_pages": 63, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=SUBLOCADE&page=8&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=SUBLOCADE&page=6&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-30T19:11:06.352Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03511118", "title": "Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Lactating Women on Select DOI", "Breastfed Infants of Mothers on Select DOI" ], "interventions": [ { "name": "Tranexamic acid (TXA)", "type": "DRUG" }, { "name": "labetalol", "type": "DRUG" }, { "name": "metformin", "type": "DRUG" }, { "name": "nifedipine", "type": "DRUG" }, { "name": "clindamycin", "type": "DRUG" }, { "name": "oxycodone", "type": "DRUG" }, { "name": "azithromycin", "type": "DRUG" }, { "name": "escitalopram", "type": "DRUG" }, { "name": "sertraline", "type": "DRUG" }, { "name": "ondansetron", "type": "DRUG" }, { "name": "Ciprofloxacin", "type": "DRUG" }, { "name": "Doxycycline", "type": "DRUG" }, { "name": "Levofloxacin", "type": "DRUG" }, { "name": "Methylphenidate", "type": "DRUG" }, { "name": "Sumatriptan", "type": "DRUG" }, { "name": "Citalopram", "type": "DRUG" }, { "name": "Cyclobenzaprine", "type": "DRUG" }, { "name": "Furosemide", "type": "DRUG" }, { "name": "Gabapentin", "type": "DRUG" }, { "name": "Hydrochlorothiazide", "type": "DRUG" }, { "name": "Hydroxyurea", "type": "DRUG" }, { "name": "Rosuvastatin", "type": "DRUG" }, { "name": "Topiramate", "type": "DRUG" }, { "name": "Trazodone", "type": "DRUG" }, { "name": "Valganciclovir", "type": "DRUG" }, { "name": "Venlafaxine", "type": "DRUG" }, { "name": "Verapamil", "type": "DRUG" }, { "name": "Remdesivir", "type": "DRUG" }, { "name": "Anakinra", "type": "DRUG" }, { "name": "Tocilizumab", "type": "DRUG" }, { "name": "Fluvoxamine", "type": "DRUG" }, { "name": "Amoxicillin", "type": "DRUG" }, { "name": "Bupropion", "type": "DRUG" }, { "name": "Duloxetine", "type": "DRUG" }, { "name": "Hydrocodone", "type": "DRUG" }, { "name": "Levetiracetam", "type": "DRUG" }, { "name": "Paroxetine", "type": "DRUG" }, { "name": "Buprenorphine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 1600, "start_date": "2018-10-04", "completion_date": "2028-07-31", "has_results": false, "last_update_posted_date": "2026-07-29", "last_synced_at": "2026-10-30T19:11:06.352Z", "location_count": 20, "location_summary": "La Jolla, California • Loma Linda, California • Chicago, Illinois + 15 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Loma Linda", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT03511118" }, { "nct_id": "NCT05529225", "title": "Evaluating the Efficacy of a Digital Platform to Deliver Comprehensive Treatment for Opioid Use Disorder", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Opioid Use Disorder" ], "interventions": [], "intervention_types": [], "sponsor": "Boulder Care", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 159, "start_date": "2021-04-01", "completion_date": "2023-01-31", "has_results": false, "last_update_posted_date": "2023-02-08", "last_synced_at": "2026-10-30T19:11:06.352Z", "location_count": 2, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" }, { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT05529225" }, { "nct_id": "NCT02665208", "title": "A Pilot Text Messaging Intervention to Reduce Smoking in Office-based Buprenorphine and Inpatient Detoxification Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Smoking Cessation" ], "interventions": [ { "name": "Treatment As Usual (TAU)", "type": "OTHER" }, { "name": "Nicotine Replacement Therapies", "type": "DRUG" }, { "name": "Text Message Intervention (TMI)", "type": "BEHAVIORAL" } ], "intervention_types": [ "OTHER", "DRUG", "BEHAVIORAL" ], "sponsor": "NYU Langone Health", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 203, "start_date": "2015-03", "completion_date": "2017-09", "has_results": false, "last_update_posted_date": "2017-12-06", "last_synced_at": "2026-10-30T19:11:06.352Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02665208" }, { "nct_id": "NCT01452789", "title": "Blinded Trial of Buprenorphine or Morphine in the Treatment of the Neonatal Abstinence Syndrome", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Neonatal Abstinence Syndrome" ], "interventions": [ { "name": "sublingual buprenorphine", "type": "DRUG" }, { "name": "oral morphine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Thomas Jefferson University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 63, "start_date": "2011-11", "completion_date": "2016-06", "has_results": true, "last_update_posted_date": "2020-03-24", "last_synced_at": "2026-10-30T19:11:06.352Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01452789" }, { "nct_id": "NCT07469501", "title": "Comparing Outpatient Treatment Retention Among Individuals Using Fentanyl Randomized to Low-dose and Direct-to-inject Buprenorphine Initiation", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Opioid Use Disorder", "Fentanyl" ], "interventions": [ { "name": "Injectable buprenorphine", "type": "DRUG" }, { "name": "Sublingual Buprenorphine (SUBOXONE, Zubsolv, or generic tablets)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2026-06", "completion_date": "2027-05", "has_results": false, "last_update_posted_date": "2026-03-13", "last_synced_at": "2026-10-30T19:11:06.352Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07469501" }, { "nct_id": "NCT01843023", "title": "Extended Release Naltrexone for Opioid-Dependent Youth", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Drug Dependence" ], "interventions": [ { "name": "Extended Release Naltrexone", "type": "DRUG" }, { "name": "Psychosocial Treatment", "type": "BEHAVIORAL" }, { "name": "Buprenorphine", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BEHAVIORAL" ], "sponsor": "Friends Research Institute, Inc.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "15 Years", "maximum_age": "21 Years", "sex": "ALL", "summary": "15 Years to 21 Years" }, "enrollment_count": 288, "start_date": "2013-06", "completion_date": "2019-07", "has_results": true, "last_update_posted_date": "2021-11-10", "last_synced_at": "2026-10-30T19:11:06.352Z", "location_count": 2, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01843023" }, { "nct_id": "NCT05942313", "title": "Predicting and Preventing Adverse Maternal and Child Outcomes of Opioid Use Disorder in Pregnancy", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Opioid Use Disorder", "Pregnancy Related" ], "interventions": [ { "name": "Buprenorphine/ Methadone exposure", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ilana Hull", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 100, "start_date": "2023-08-28", "completion_date": "2026-12-01", "has_results": false, "last_update_posted_date": "2026-08-06", "last_synced_at": "2026-10-30T19:11:06.352Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT05942313" }, { "nct_id": "NCT02276989", "title": "Evaluation of a Compliance Marker in Prescription Opioid Abusers With Chronic Pain", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Compliance", "Chronic Pain" ], "interventions": [ { "name": "acetazolamide", "type": "DRUG" }, { "name": "Quinine", "type": "DRUG" }, { "name": "Riboflavin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Georgetown University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 0, "start_date": "2014-12", "completion_date": "2016-01", "has_results": false, "last_update_posted_date": "2017-02-10", "last_synced_at": "2026-10-30T19:11:06.352Z", "location_count": 1, "location_summary": "Washington D.C., District of Columbia", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02276989" }, { "nct_id": "NCT02510014", "title": "Safety and Tolerability Study of Depot Buprenorphine in Treatment Seeking Subjects With Opioid Use Disorder", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Opioid Use Disorder", "Opioid-related Disorders" ], "interventions": [ { "name": "SUBOXONE sublingual film", "type": "DRUG" }, { "name": "RBP-6000", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Indivior Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 775, "start_date": "2015-07-27", "completion_date": "2017-01-31", "has_results": true, "last_update_posted_date": "2018-03-29", "last_synced_at": "2026-10-30T19:11:06.352Z", "location_count": 42, "location_summary": "Haleyville, Alabama • Hamilton, Alabama • Little Rock, Arkansas + 37 more", "locations": [ { "city": "Haleyville", "state": "Alabama" }, { "city": "Hamilton", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Garden Grove", "state": "California" }, { "city": "Glendale", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02510014" }, { "nct_id": "NCT05427981", "title": "Anti-suicidal Effects of Buprenorphine In Depressed Individuals", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Suicidal Ideation", "Major Depressive Disorder" ], "interventions": [ { "name": "Belbuca Buccal Product", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "New York State Psychiatric Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 0, "start_date": "2022-10-10", "completion_date": "2024-01-14", "has_results": false, "last_update_posted_date": "2023-11-14", "last_synced_at": "2026-10-30T19:11:06.352Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05427981" } ] }